News

The drug, AN2690, is designed to treat onychomycosis, a fungal infection of the nail and nail bed, that affects seven to 10% of the US population. Under the

Under the contract extension, Bayer will continue to supply Helixate FS to CSL Behring through 2017. At the same time, the companies settled outstanding litigation relating to the

The Bioral product for which the application was filed is an enchocleated version of amphotericin B (CAMB), an antifungicidal agent. Amphotericin B is used for treating infections such

CT-322 is a proprietary Adnectin protein therapeutic that specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis pathway. As a result,

The company now anticipates that agency will complete its review and issue its opinion regarding approval within the next 90 days. Genasense is a novel targeted therapy that

Arixtra, an injectable drug, is now indicated for patients with unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) and ST-segment elevation myocardial infarction (STEMI). UA/NSTEMI and STEMI

The data extend positive results from a previous preclinical study in which treatment with the compound HE3286, initiated at disease onset, significantly reduced the illness. In that previous

The trial also evaluated the effectiveness of Oracea for maintenance therapy in the treatment of rosacea. Rosacea is characterized by the appearance of inflammatory lesions, skin redness and

Mitsubishi Pharma, owned by Mitsubishi Chemical Holdings, will hold the majority shares of the new business owning 56.4% of the new company. Japanese pharmaceutical companies are increasingly entering